Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N4O2 |
Molecular Weight | 336.3877 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=C(\C=C2/NC(=O)\C(NC2=O)=C\C3=CC=CC=C3)N=CN1
InChI
InChIKey=UNRCMCRRFYFGFX-TYPNBTCFSA-N
InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
Plinabulin (formerly known as NPI-2358) is a potent microtubule-destabilizing agent that exerts its effect by binding to the colchicine-binding site of tubulin. Plinabulin projects its potent antitumor activity against a broad spectrum of tumor cell lines. This drug in combination with docetaxel is under development by BeyondSpring Pharmaceuticals in a worldwide Phase 3 clinical trial for non-small cell lung cancer. Pegfilgrastim is also in phase II clinical trial for the prevention of chemotherapy-induced neutropenia, where docetaxel, doxorubicin, and cyclophosphamide (TAC) were used as the chemotherapy. Plinabulin also possessed antitumor activity in animal models with multiple myeloma cancer cells, where the JNK protein appeared to be a primary target of plinabulin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16317287 |
|||
Target ID: P45983|||Q308M2 Gene ID: 5599.0 Gene Symbol: MAPK8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21454451 |
|||
Target ID: P45984|||Q15711 Gene ID: 5601.0 Gene Symbol: MAPK9 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21454451 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg/m2 1 times / week multiple, intravenous RP2D Dose: 30 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 30 mg/m2, 1 times / week Sources: Page: p.5895 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.5895 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
yes [IC50 0.53 uM] | ||||
yes [IC50 1.24 uM] | ||||
yes [IC50 4.23 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02504489
Docetaxel + Plinabulin (DP): on days 1 and 8 of the 21 day cycle, patients will receive plinabulin (P) administered via IV infusion over 30 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On day 8, plinabulin infusion will be repeated.
On Day 1, no pre-medication will be routinely administered for plinabulin infusion. Anti-emetics may be prescribed as indicated according to institutional guidelines for chemotherapy. On Day 8, antiemetic prophylaxis may be administered prior to plinabulin infusion.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21454451
Human multiple myeloma (MM) cell lines MM.1S, MM.1R (Dex-resistant), RPMI-8226, and INA-6 (IL-6–dependent) were treated with plinabulin at different concentrations (range, 1nM to 10μM) for 24, 48, and 72 hours, and cell viability was measured by MTT assays. As a result, plinabulin significantly decreased the viability of all the MM cell lines in a time- and dose-dependent manner (IC50 ranges from 8nM to 10nM for different cell lines).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67421
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9949641
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
986FY7F8XR
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
DTXSID201031311
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
DB05992
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
WW-68
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
100000175028
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
9206
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1096380
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
PLINABULIN
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
C62444
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | |||
|
m8924
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
714272-27-2
Created by
admin on Sat Dec 16 17:43:05 GMT 2023 , Edited by admin on Sat Dec 16 17:43:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY